先聲藥業(02096.HK):與G1合作的創新藥注射用Trilaciclib增加新適應症的臨牀試驗申請獲批
格隆匯6月14日丨先聲藥業(02096.HK)公佈,2021年6月10日,集團與G1 Therapeutics, INC.(“G1”)合作的創新藥注射用Trilaciclib增加新適應症的臨牀試驗申請已獲得中國國家藥品監督管理局批准。根據該批准通知書,集團與合作伙伴G1計劃開展一項評估Trilaciclib或安慰劑在一線或二線接受吉西他濱和卡鉑化療的不可切除的局部晚期或轉移性三陰性乳腺癌患者中療效的III期、隨機、雙盲研究。
公吿顯示,G1 Therapeutics, Inc.是一家商業階段的生物製藥公司,專注於發現、開發和交付旨在改善癌症患者生活的下一代療法,包括其首款商用產品COSELATM,一種旨在改善接受化學治療的患者的預後的首創療法。
公司是一家從事藥品研發、生產和商業化的公司,擁有“轉化醫學與創新藥物國家重點實驗室”。公司在以下專注的戰略性治療領域擁有多元化的產品組合:(i)腫瘤疾病、(ii)中樞神經系統疾病及(iii)自身免疫疾病,並佔據相應細分治療領域市場領先地位及╱或擁有卓越往績記錄。公司持續深化開放式創新,與多家跨國藥企建立戰略合作夥伴關係。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.